Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Shire Clear all
Completed Phase 2 Interventional Results available

A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations

NCT02204579
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
NPSP795
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects

NCT01989169
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, SSP-004184SS
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT00462709
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
48
States / cities
Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)

NCT01905540
View directory record Official record
Conditions
Healthy
Interventions
SSP-004184AQ, SSP-004184SS
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

NCT00914966
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 inhibitor (human) [C1 INH]
Biological
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Wheaton, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT01472939
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Tucson, Arizona • Beverly Hills, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers

NCT00925704
View directory record Official record
Conditions
Healthy
Interventions
Calcitriol, Lanthanum carbonate + Calcitriol, Sevelamer carbonate + Calcitriol
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01442688
View directory record Official record
Conditions
Healthy
Interventions
Amoxicillin + MMX placebo, Amoxicillin + MMX mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

NCT00438815
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
30
States / cities
Scottsdale, Arizona • Bentonville, Arkansas • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Results available

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

NCT01457339
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection

NCT00952822
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed No phase listed Observational

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

NCT03185897
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Non-treatment, seroprevalence
Other
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • East Lansing, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

NCT01268098
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
NPSP558
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Lakewood, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects

NCT03150108
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

BAX 855 Pediatric Study

NCT02210091
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 11 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects

NCT01979185
View directory record Official record
Conditions
Healthy
Interventions
Simvastatin, SSP-004184SS
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Approved For Marketing No phase listed Expanded access

Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

NCT00954460
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
velaglucerase alfa
Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years and older
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

NCT01259726
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
VP20621, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Modesto, California • Palm Desert, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

NCT03277313
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 1, 2026, 11:07 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)

NCT03566823
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate

NCT00458289
View directory record Official record
Conditions
Hyperphosphatemia in Chronic Kidney Disease
Interventions
Lanthanum carbonate (chewed vs. crushed)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

NCT01620255
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, PF-00547659 SC Injection
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
99
States / cities
Scottsdale, Arizona • La Jolla, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 1, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Results available

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 1, 2026, 11:07 PM EDT